Circulation analysis of SELECT reports a 37.8% drop in inflammation with semaglutide

A new analysis of the SELECT cardiovascular outcomes trial reports that semaglutide cut high-sensitivity C-reactive protein (hsCRP), a blood marker of inflammation, by 37.8% by week 104. The prespecified secondary analysis was published in Circulation and indexed in August 2026 ^[1].

According to the study summary, reductions in hsCRP appeared early, with measurable drops at weeks 4 and 8 — well before most participants would have reached their full weight loss ^[1]. The authors also report that hsCRP fell among participants who lost little weight, but they stopped short of concluding that semaglutide reduces inflammation through a mechanism independent of weight loss ^[1].

That caution matters. Early and weight-independent signals are consistent with a direct anti-inflammatory effect, but they do not prove one. Weight loss, changes in blood sugar, shifts in diet, and other downstream effects can all move inflammation markers, and a secondary analysis of a single trial cannot fully separate those threads.

What the sources do and don't show

The development is drawn from a PubMed record for the Circulation paper, and the full text was not retrievable at the time of writing ^[1]. That leaves several important details unconfirmed.

Not yet known from the available source: the baseline and follow-up hsCRP values in absolute terms, the size of the change in the placebo group, how many participants were included in the low-weight-loss subgroup, and how the subgroups were defined. Also not established here is whether the drop in hsCRP tracked with the reduction in heart attacks, strokes and cardiovascular deaths that SELECT originally reported — in other words, whether lower inflammation helps explain the benefit or is simply something that happens alongside it ^[1].

Semaglutide is the active ingredient in Ozempic and Rybelsus, approved for type 2 diabetes, and in Wegovy, approved for weight management and, in the United States, for reducing cardiovascular risk in certain adults. SELECT was the large trial in adults with overweight or obesity and established cardiovascular disease that supported that cardiovascular indication. The specific enrollment figures, dosing and follow-up details of the parent trial are not restated in the source available here ^[1].

Why it matters for patients

For people already taking or considering a GLP-1 medication, this analysis does not change what the drug is approved for, how it is prescribed, or what insurers cover. It is a secondary look at blood samples from a trial that has already reported its main results.

What it adds is a possible piece of the "how" behind semaglutide's cardiovascular findings. If part of the benefit comes from lowering inflammation rather than from pounds lost, that would be relevant to patients who see only modest weight loss on the medication — a group that has historically been hard to counsel, because weight change is the most visible measure of whether a drug is "working." The analysis reports hsCRP reductions even in people with little weight loss, though the authors do not claim this settles the mechanism question ^[1].

It is also worth noting what a marker is and is not. hsCRP is a lab value, not an outcome. A 37.8% drop is a change in a number on a blood test; whether that translates into fewer cardiovascular events for a given individual is a separate question that a secondary analysis cannot answer on its own ^[1].

What happens next

The Circulation paper appeared in the medical literature in August 2026 ^[1]. Independent commentary, editorials and replication in other GLP-1 trial datasets would be the usual next steps, but no specific follow-up studies or regulatory reviews tied to this analysis are described in the available source. Anyone weighing what this means for their own treatment would need to discuss it with their clinician.